Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod 0.5 mg vs placebo in primary progressive multiple sclerosis
2007-002627-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Fingolimod 0.5 mg with Placebo (2 arms). Primary endpoint: Time to sustained disability progression. Started Apr 2008; status: completed.
02
Drugs
fingolimod
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2007-002627-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002627-32.